Search

Your search keyword '"Zallio, F"' showing total 154 results
Start Over Author "Zallio, F"
154 results on '"Zallio, F"'

1. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study

Author

Malfona, F., Tanasi, I., Piccini, M., Papayannidis, C., Federico, V., Mancini, V., Roncoroni, E., Todisco, E., Bianchi, S., Ciotti, G., Chiusolo, Patrizia, Gentile, M., Gianfelici, V., Giglio, F., Malagola, M., Mule, A., Saraceni, F., Vetro, C., Zallio, F., Cappelli, L. V., Pizzolo, G., Foa, Robin, Bonifacio, M., Chiaretti, S., Chiusolo P. (ORCID:0000-0002-1355-1587), Foa R., Malfona, F., Tanasi, I., Piccini, M., Papayannidis, C., Federico, V., Mancini, V., Roncoroni, E., Todisco, E., Bianchi, S., Ciotti, G., Chiusolo, Patrizia, Gentile, M., Gianfelici, V., Giglio, F., Malagola, M., Mule, A., Saraceni, F., Vetro, C., Zallio, F., Cappelli, L. V., Pizzolo, G., Foa, Robin, Bonifacio, M., Chiaretti, S., Chiusolo P. (ORCID:0000-0002-1355-1587), and Foa R.

Abstract

N/A

Published
2024

3. Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)

Author

Russo, D, Polverelli, N, Malagola, M, Farina, M, Leoni, A, Bernardi, S, Mammoliti, S, Sacchi, N, Martino, M, Ciceri, F, Zallio, F, Olivieri, A, Falcioni, S, Storti, G, Michieli, M, Carluccio, P, Grassi, A, Oldani, E, Bonifazi, F, Prete, A, Cavattoni, I, Maffeis, M, Pastore, D, Vacca, A, Caravelli, D, Mirabile, M, Mordini, N, Nozzoli, C, Faraci, M, Federico, V, Ronconi, S, Skert, C, Onida, F, Marcatti, M, Piemontese, S, Narni, F, Balduzzi, A, De Simone, G, Picardi, A, De Gobbi, M, Calore, E, Tringali, S, Zecca, M, Secondino, S, Guiducci, B, Pelosini, M, Zuffa, E, Facchini, L, Imola, M, Iori, A, Proia, A, Sica, S, Armiento, D, Carella, A, Dellacasa, C, Fagioli, F, Rabusin, M, Ferrario, A, Elice, F, Russo D., Polverelli N., Malagola M., Farina M., Leoni A., Bernardi S., Mammoliti S., Sacchi N., Martino M., Ciceri F., Zallio F., Olivieri A., Falcioni S., Storti G., Michieli M., Carluccio P., Grassi A., Oldani E., Bonifazi F., Prete A., Cavattoni I. M., Maffeis M., Pastore D., Vacca A., Caravelli D., Mirabile M., Mordini N., Nozzoli C., Faraci M., Federico V., Ronconi S., Skert C., Onida F., Marcatti M., Piemontese S., Narni F., Balduzzi A., De Simone G., Picardi A., De Gobbi M., Calore E., Tringali S., Zecca M., Secondino S., Guiducci B., Pelosini M., Zuffa E., Facchini L., Imola M., Iori A. P., Proia A., Sica S., Armiento D., Carella A. M., Dellacasa C. M., Fagioli F., Rabusin M., Ferrario A., Elice F., Russo, D, Polverelli, N, Malagola, M, Farina, M, Leoni, A, Bernardi, S, Mammoliti, S, Sacchi, N, Martino, M, Ciceri, F, Zallio, F, Olivieri, A, Falcioni, S, Storti, G, Michieli, M, Carluccio, P, Grassi, A, Oldani, E, Bonifazi, F, Prete, A, Cavattoni, I, Maffeis, M, Pastore, D, Vacca, A, Caravelli, D, Mirabile, M, Mordini, N, Nozzoli, C, Faraci, M, Federico, V, Ronconi, S, Skert, C, Onida, F, Marcatti, M, Piemontese, S, Narni, F, Balduzzi, A, De Simone, G, Picardi, A, De Gobbi, M, Calore, E, Tringali, S, Zecca, M, Secondino, S, Guiducci, B, Pelosini, M, Zuffa, E, Facchini, L, Imola, M, Iori, A, Proia, A, Sica, S, Armiento, D, Carella, A, Dellacasa, C, Fagioli, F, Rabusin, M, Ferrario, A, Elice, F, Russo D., Polverelli N., Malagola M., Farina M., Leoni A., Bernardi S., Mammoliti S., Sacchi N., Martino M., Ciceri F., Zallio F., Olivieri A., Falcioni S., Storti G., Michieli M., Carluccio P., Grassi A., Oldani E., Bonifazi F., Prete A., Cavattoni I. M., Maffeis M., Pastore D., Vacca A., Caravelli D., Mirabile M., Mordini N., Nozzoli C., Faraci M., Federico V., Ronconi S., Skert C., Onida F., Marcatti M., Piemontese S., Narni F., Balduzzi A., De Simone G., Picardi A., De Gobbi M., Calore E., Tringali S., Zecca M., Secondino S., Guiducci B., Pelosini M., Zuffa E., Facchini L., Imola M., Iori A. P., Proia A., Sica S., Armiento D., Carella A. M., Dellacasa C. M., Fagioli F., Rabusin M., Ferrario A., and Elice F.

Abstract

The Transplant Centers belonging to Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) conducted a survey with the aim of evaluating the effect of SARS-CoV2 pandemic on the allogeneic transplant activity in Italy. The pandemic period from 1/3/2020 to 31/7/2020 was compared with the same period in 2019. Overall, in 2020 there was a 2.4% reduction in the number of allo-HCT cases compared to 2019. Interestingly, this deflection did not affect the acute leukemia cases (+5.7% in 2020). The use of peripheral blood-derived stem cells (+10.7%) and cryopreservation (97.4% of the centers) was highly adopted in 2020. Despite the sanitary emergency, almost all of the surveyed centers declared no impact of SARS-CoV2 pandemic on the transplant timing and outcomes, and the sanitary policy was positively evaluated by the majority of centers. The emergency measures ensured that only a minority of the allo-HCT patients had been infected by SARS-CoV2; however, a mortality of 42.1% among the allo-HCT patients hospitalized for COVID-19 was recorded. This survey gives us the information that the GITMO Group reacted positively to the pandemic. Thanks to the emergency strategies, the Italian allo-HCT activity continued safely, showing only a minor deflection and offering the same probability of cure to the transplanted patients.

Published
2021

4. Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)

Author

Russo D., Polverelli N., Malagola M., Farina M., Leoni A., Bernardi S., Mammoliti S., Sacchi N., Martino M., Ciceri F., Zallio F., Olivieri A., Falcioni S., Storti G., Michieli M., Carluccio P., Grassi A., Oldani E., Bonifazi F., Prete A., Cavattoni I. M., Maffeis M., Pastore D., Vacca A., Caravelli D., Mirabile M., Mordini N., Nozzoli C., Faraci M., Federico V., Ronconi S., Skert C., Onida F., Marcatti M., Piemontese S., Narni F., Balduzzi A., De Simone G., Picardi A., De Gobbi M., Calore E., Tringali S., Zecca M., Secondino S., Guiducci B., Pelosini M., Zuffa E., Facchini L., Imola M., Iori A. P., Proia A., Sica S., Armiento D., Carella A. M., Dellacasa C. M., Fagioli F., Rabusin M., Ferrario A., Elice F., Russo, D, Polverelli, N, Malagola, M, Farina, M, Leoni, A, Bernardi, S, Mammoliti, S, Sacchi, N, Martino, M, Ciceri, F, Zallio, F, Olivieri, A, Falcioni, S, Storti, G, Michieli, M, Carluccio, P, Grassi, A, Oldani, E, Bonifazi, F, Prete, A, Cavattoni, I, Maffeis, M, Pastore, D, Vacca, A, Caravelli, D, Mirabile, M, Mordini, N, Nozzoli, C, Faraci, M, Federico, V, Ronconi, S, Skert, C, Onida, F, Marcatti, M, Piemontese, S, Narni, F, Balduzzi, A, De Simone, G, Picardi, A, De Gobbi, M, Calore, E, Tringali, S, Zecca, M, Secondino, S, Guiducci, B, Pelosini, M, Zuffa, E, Facchini, L, Imola, M, Iori, A, Proia, A, Sica, S, Armiento, D, Carella, A, Dellacasa, C, Fagioli, F, Rabusin, M, Ferrario, A, Elice, F, Russo, D., Polverelli, N., Malagola, M., Farina, M., Leoni, A., Bernardi, S., Mammoliti, S., Sacchi, N., Martino, M., Ciceri, F., Zallio, F., Olivieri, A., Falcioni, S., Storti, G., Michieli, M., Carluccio, P., Grassi, A., Oldani, E., Bonifazi, F., Prete, A., Cavattoni, I. M., Maffeis, M., Pastore, D., Vacca, A., Caravelli, D., Mirabile, M., Mordini, N., Nozzoli, C., Faraci, M., Federico, V., Ronconi, S., Skert, C., Onida, F., Marcatti, M., Piemontese, S., Narni, F., Balduzzi, A., De Simone, G., Picardi, A., De Gobbi, M., Calore, E., Tringali, S., Zecca, M., Secondino, S., Guiducci, B., Pelosini, M., Zuffa, E., Facchini, L., Imola, M., Iori, A. P., Proia, A., Sica, S., Armiento, D., Carella, A. M., Dellacasa, C. M., Fagioli, F., Rabusin, M., Ferrario, A., and Elice, F.

Subjects
Homologous, Myeloid, medicine.medical_specialty, 2019-20 coronavirus outbreak, Bone marrow transplant, Coronavirus disease 2019 (COVID-19), Epidemiology, medicine.medical_treatment, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Hematopoietic stem cell transplantation, Acute, Humans, Italy, Pandemics, RNA, Viral, SARS-CoV-2, Stem Cell Transplantation, Transplantation, Homologous, COVID-19, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Article, hematopoietic stem cell transplantation, covid-19, pandemic, Internal medicine, Pandemic, medicine, Viral, Acute leukemia, Transplantation, Leukemia, business.industry, Hematology, Stem-cell research, RNA, Stem cell, business
Abstract

The Transplant Centers belonging to Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) conducted a survey with the aim of evaluating the effect of SARS-CoV2 pandemic on the allogeneic transplant activity in Italy. The pandemic period from 1/3/2020 to 31/7/2020 was compared with the same period in 2019. Overall, in 2020 there was a 2.4% reduction in the number of allo-HCT cases compared to 2019. Interestingly, this deflection did not affect the acute leukemia cases (+5.7% in 2020). The use of peripheral blood-derived stem cells (+10.7%) and cryopreservation (97.4% of the centers) was highly adopted in 2020. Despite the sanitary emergency, almost all of the surveyed centers declared no impact of SARS-CoV2 pandemic on the transplant timing and outcomes, and the sanitary policy was positively evaluated by the majority of centers. The emergency measures ensured that only a minority of the allo-HCT patients had been infected by SARS-CoV2; however, a mortality of 42.1% among the allo-HCT patients hospitalized for COVID-19 was recorded. This survey gives us the information that the GITMO Group reacted positively to the pandemic. Thanks to the emergency strategies, the Italian allo-HCT activity continued safely, showing only a minor deflection and offering the same probability of cure to the transplanted patients.

Published
2021

5. Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation

Author

Delia, M., Carluccio, P., Gagliardi, V. P., Mestice, A., Chiusolo, Patrizia, Arpinati, M., Milone, G. A., Martino, M., Mazza, P., Ingrosso, C., Vacca, A., Saporiti, G., Zallio, F., Attolico, I., Pastore, D., Specchia, G., Albano, F., Musto, P., Chiusolo P. (ORCID:0000-0002-1355-1587), Delia, M., Carluccio, P., Gagliardi, V. P., Mestice, A., Chiusolo, Patrizia, Arpinati, M., Milone, G. A., Martino, M., Mazza, P., Ingrosso, C., Vacca, A., Saporiti, G., Zallio, F., Attolico, I., Pastore, D., Specchia, G., Albano, F., Musto, P., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

N/A

Published
2022

8. Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation - Bridging to transplantation

Author

Crisà, E., primary, Zallio, F., additional, Zacchi, G., additional, Cerrano, M., additional, Rivolta, G., additional, Ferrero, D., additional, Deambrogi, C., additional, Essa, W., additional, Awikeh, B., additional, Nicolosi, M., additional, Santini, V., additional, Gaidano, G., additional, Bruno, B., additional, and Patriarca, A., additional

Published
2021
Full Text
View/download PDF

9. Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti

Author

Picardi, A., Sacchi, N., Miotti, V., Lorentino, F., Oldani, E., Rambaldi, A., Sessa, M., Bruno, B., Cerno, M., Vago, L., Bernasconi, P., Arcese, W., Benedetti, F., Pioltelli, P., Russo, D., Farina, L., Fagioli, F., Guidi, S., Saporiti, G., Zallio, F., Chiusolo, Patrizia, Borghero, C., Papalinetti, G., La Rocca, U., Milone, G., Lamparelli, T., Carella, A. M., Luppi, M., Olivieri, A., Martino, M., Carluccio, P., Celeghini, I., Andreani, M., Gallina, A. M., Patriarca, F., Pollichieni, S., Mammoliti, S., Micciche, S., Mangione, I., Ciceri, F., Bonifazi, F., Chiusolo P. (ORCID:0000-0002-1355-1587), Picardi, A., Sacchi, N., Miotti, V., Lorentino, F., Oldani, E., Rambaldi, A., Sessa, M., Bruno, B., Cerno, M., Vago, L., Bernasconi, P., Arcese, W., Benedetti, F., Pioltelli, P., Russo, D., Farina, L., Fagioli, F., Guidi, S., Saporiti, G., Zallio, F., Chiusolo, Patrizia, Borghero, C., Papalinetti, G., La Rocca, U., Milone, G., Lamparelli, T., Carella, A. M., Luppi, M., Olivieri, A., Martino, M., Carluccio, P., Celeghini, I., Andreani, M., Gallina, A. M., Patriarca, F., Pollichieni, S., Mammoliti, S., Micciche, S., Mangione, I., Ciceri, F., Bonifazi, F., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

HLA molecules are important for immunoreactivity in allogeneic hematopoietic stem cell transplantation (HSCT). The Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti promoted a retrospective observational study to evaluate HLA matching and the impact of allelic HLA mismatching and non-HLA factors on unrelated Italian HSCT outcomes. From 2012 to 2015, 1788 patients were enrolled in the study. The average donor age was 29 years and the average recipient age was 49 years. As a conditioning regimen, 71% of the patients received myeloablative conditioning. For GVHD prophylaxis, 76% received either antithymocyte or anti-T lymphocyte globulin, cyclosporine A, and methotrexate. Peripheral blood was the stem cell source in 80%. The median duration of follow-up was 53 months. Regarding HLA matching, 50% of donor-recipient pairs were 10/10 matched, 38% had 1 mismatch, and 12% had 2 or more mismatches. A total of 302 pairs shared Italian origin. Four-year overall survival (OS), progression-free survival, GVHD-free relapse-free survival, and relapse rates were 49%, 40%, 22%, and 34%, respectively. The 4-year NRM was 27%, and the 100-day cumulative incidence of grade ≥II acute GVHD (aGVHD) was 26%. In multivariate analysis, 9/10 and ≤8/10 HLA allele-matched pairs were associated with worse OS (P = .04 and. 007, respectively), NRM (P = .007 and P < .0001, respectively), and grade III-IV aGVHD (P = .0001 and. 01, respectively). Moreover, the incidences of grade II-IV aGVHD (P = .001) and chronic GVHD (P = .002) were significantly lower in Italian pairs. In conclusion, 10/10 HLA matching is a favorable prognostic factor for unrelated HSCT outcome in the Italian population. Moreover, the presence of 2 HLA-mismatched loci was associated with a higher NRM (P < .0001) and grade II-IV aGVHD (P = .006) and a poorer OS (P = .001) compared with 1 HLA-mismatched loc

Published
2021

10. The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Author

Delia, M., Carluccio, P., Mestice, A., Chiusolo, Patrizia, Metafuni, Elisabetta, Bellesi, Silvia, Arpinati, M., Milone, G. A., Martino, M., Mazza, P., Ingrosso, C., Vacca, A., Saporiti, G., Zallio, F., Attolico, I., Pastore, D., Specchia, G., Albano, F., Musto, P., Chiusolo P. (ORCID:0000-0002-1355-1587), Metafuni E., Bellesi S., Delia, M., Carluccio, P., Mestice, A., Chiusolo, Patrizia, Metafuni, Elisabetta, Bellesi, Silvia, Arpinati, M., Milone, G. A., Martino, M., Mazza, P., Ingrosso, C., Vacca, A., Saporiti, G., Zallio, F., Attolico, I., Pastore, D., Specchia, G., Albano, F., Musto, P., Chiusolo P. (ORCID:0000-0002-1355-1587), Metafuni E., and Bellesi S.

Abstract

Although it is well known that tumor site- or bone marrow-infiltrating regulatory T cells (Tregs) might be correlated with worse outcomes in solid tumors and acute leukemias by promoting immune surveillance escape, their contribution to the immediate post-allogeneic transplantation phase by peripheral blood (PB) allografts remains unclear. Moreover, the Treg content in stem cells harvested from PB has been suggested to be correlated with acute graft versus-host-disease (aGVHD) and immunologic recovery after allogeneic PB stem cell transplantation (allo-PBSCT). This study aimed to investigate the impact of the graft content of Tregs, as graft CD3+/Tregs ratio (gCD3/TregsR), on acute GVHD and post-allo-PBSCT outcomes. We prospectively enrolled 94 consecutive patients at 9 Italian centers of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) with acute myelogenous (n = 71; 75%) or lymphoblastic (n = 23; 25%) leukemia in complete remission who underwent matched related donor (n = 35; 37%) or unrelated donor (n = 59; 63%) allo-PBSCT. The median graft CD3+ cell, Treg, and gCD3/TregsR values were 196 × 106/kg body weight (range, 17 to 666 × 106/kg), 3 × 106/kg (range, 0.1 to 35 × 106/kg), and 71 (range, 1 to 1883), respectively. The discriminatory power of the gCD3/TregsR value to predict grade ≥II aGVHD was assessed by estimating the area under the receiver operating characteristic (ROC) curve (AUC). Any grade and grade ≥II aGVHD occurred in 24 (26%) and 17 (18%) allo-PBSCT recipients, respectively. By ROC analysis, AUC (0.74; 95% confidence interval [CI], 0.608 to 0.866; P =.002) identified 70 as the optimal gCD3/TregsR cutoff value predicting the appearance of grade ≥II aGVHD with 76% sensitivity and 71% specificity. Patients were subdivided into a high (ROC curve value ≥70) gCD3/TregsR group (HR; n = 48) and a low (ROC curve value <70) gCD3/TregsR group (LR; n = 46). The incidence of grade II-IV aGVHD was lower in the LR group compared with the HR group (9% [4 o

Published
2021

25. Predicting failure of hematopoietic stem cell mobilization before it starts: The predicted poor mobilizer (pPM) score

Author

Olivieri, J., Attolico, I., Nuccorini, R., Pascale, S. P., Chiarucci, M., Poiani, M., Corradini, P., Farina, L., Gaidano, G., Nassi, L., Sica, S., Piccirillo, N., Pioltelli, P. E., Martino, M., Moscato, T., Pini, M., Zallio, F., Ciceri, F., Marktel, S., Mengarelli, A., Musto, P., Capria, S., Merli, F., Codeluppi, K., Mele, G., Lanza, F., Specchia, G., Pastore, D., Milone, G., Saraceni, F., Di Nardo, E., Perseghin, P., Olivieri, A., Sica S. (ORCID:0000-0003-2426-3465), Piccirillo N. (ORCID:0000-0002-1688-1987), Olivieri, J., Attolico, I., Nuccorini, R., Pascale, S. P., Chiarucci, M., Poiani, M., Corradini, P., Farina, L., Gaidano, G., Nassi, L., Sica, S., Piccirillo, N., Pioltelli, P. E., Martino, M., Moscato, T., Pini, M., Zallio, F., Ciceri, F., Marktel, S., Mengarelli, A., Musto, P., Capria, S., Merli, F., Codeluppi, K., Mele, G., Lanza, F., Specchia, G., Pastore, D., Milone, G., Saraceni, F., Di Nardo, E., Perseghin, P., Olivieri, A., Sica S. (ORCID:0000-0003-2426-3465), and Piccirillo N. (ORCID:0000-0002-1688-1987)

Abstract

Predicting mobilization failure before it starts may enable patient-tailored strategies. Although consensus criteria for predicted PM (pPM) are available, their predictive performance has never been measured on real data. We retrospectively collected and analyzed 1318 mobilization procedures performed for MM and lymphoma patients in the plerixafor era. In our sample, 180/1318 (13.7%) were PM. The score resulting from published pPM criteria had sufficient performance for predicting PM, as measured by AUC (0.67, 95%CI: 0.63-0.72). We developed a new prediction model from multivariate analysis whose score (pPM-score) resulted in better AUC (0.80, 95%CI: 0.76-0.84, p < 0001). pPM-score included as risk factors: increasing age, diagnosis of NHL, positive bone marrow biopsy or cytopenias before mobilization, previous mobilization failure, priming strategy with G-CSF alone, or without upfront plerixafor. A simplified version of pPM-score was categorized using a cut-off to maximize positive likelihood ratio (15.7, 95%CI: 9.9-24.8); specificity was 98% (95%CI: 97-98.7%), sensitivity 31.7% (95%CI: 24.9-39%); positive predictive value in our sample was 71.3% (95%CI: 60-80.8%). Simplified pPM-score can "rule in" patients at very high risk for PM before starting mobilization, allowing changes in clinical management, such as choice of alternative priming strategies, to avoid highly likely mobilization failure.

Published
2018

27. A refined composite clinical score for the early identification of the predicted Poor Mobilizers (PM): a GITMO analysis

Author

Attolico, I., Olivieri, J., Nuccorini, R., Pascale, S. P., Chiarucci, M., Poiani, M., Gozzer, M., Capria, S., Mele, G., Melpignano, A., Perseghin, P., Pioltelli, P., Massimo Martino, Moscato, T., Musto, P., Pietrantuono, G., Corradini, P., Farina, L., Nassi, L., Casaluci, G. Margiotta, Di Marco, A., Spadaro, A., Gumenyuku, S., Marchesi, F., Lanza, F., Brambilla, P., Pini, M., Zallio, F., Marktel, S., Gattillo, S., Sica, S., Ausoni, G., Merli, F., Codeluppi, K., Specchia, G., Pastore, D., Pizzuti, M., Di Nardo, E., and Olivieri, A.

Published
2015

28. MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY)

Author

Scarfo, L, Quaresmini, G, Mauro, Fr, Orlandi, E, Reda, G, Laurenti, L, Coscia, Marta, Ambrosetti, A, Murru, R, Trentin, L, Guelill, A, Visco, C, Morabito, F, Frustaci, A, Ciolli, S, Rossini, F, Cuneo, A, Gozzetti, A, Scortechini, I, Pane, F, Zinzani, Pl, Ferrara, F, Mannina, D, Marasca, R, Pierri, I, Specchia, G, Chiarenza, A, Zallio, F, Molica, S, De Paoli, L, Torreggiani, A, Brugiatelli, M, Semenzato, G, Innocenti, I, Picardi, P, Pizzolo, G, Foa, R, Rambaldi, A, and Ghia, P.

Published
2015

30. Effect of age and previous autologous transplant on treatment-related mortality and GVHD in 140 patients treated with reduce-intensity conditioning and allograft for advanced hematological malignancies

Author

Corradini P, Zallio F, Mariotti J, Valagussa P, Dodero A, Bregni M, Bacigalupo A, Lucesole M, Patriarca F, Rambaldi A, Scime R, Bandini G, Gianni AM, Tarella C, Olivieri A., CICERI , FABIO, Corradini, P, Zallio, F, Mariotti, J, Valagussa, P, Dodero, A, Bregni, M, Ciceri, Fabio, Bacigalupo, A, Lucesole, M, Patriarca, F, Rambaldi, A, Scime, R, Bandini, G, Gianni, Am, Tarella, C, and Olivieri, A.

Published
2004

31. Graft-versus-lymphoma effect in peripheral T-cell lymphomas (PTCL): Reduced-intensity conditioning followed by allogeneic transplantation gives a better outcome than high-dose chemotherapy followed by autografting

Author

Corradini P, Dodero A, Zallio F, Cuttica A, Caracciolo D, Di Nicola M, Casini M, Narni F, Patriarca F, Boccadoro M, Gianni AM, Tarella C., CICERI , FABIO, Corradini, P, Dodero, A, Zallio, F, Cuttica, A, Caracciolo, D, Di Nicola, M, Casini, M, Ciceri, Fabio, Narni, F, Patriarca, F, Boccadoro, M, Gianni, Am, and Tarella, C.

Published
2003

34. Reduced-intensity conditioning followed by allogeneic transplantation is an effective salvage treatment for patients with hematologic malignancies failing a previous autograft

Author

Corradini P, Tarella C, Olivieri A, Dodero A, Voena C, Leoni P, Zallio F, Devizzi L, Rambaldi A, Sajeva M, Gianni A, Bregni M., CICERI , FABIO, BORDIGNON, CLAUDIO, Corradini, P, Tarella, C, Olivieri, A, Dodero, A, Voena, C, Leoni, P, Zallio, F, Ciceri, Fabio, Devizzi, L, Rambaldi, A, Sajeva, M, Bordignon, Claudio, Gianni, A, and Bregni, M.

Published
2002

35. Reduced intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in leukemias and lymphomas

Author

Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Moira L, Dodero A, Rambaldi A, Sajeva MR, Tresoldi MIO, Bregni M., CICERI , FABIO, BORDIGNON, CLAUDIO, Corradini, P, Tarella, C, Olivieri, A, Gianni, Am, Voena, C, Zallio, F, Ladetto, M, Falda, M, Moira, L, Dodero, A, Ciceri, Fabio, Rambaldi, A, Sajeva, Mr, Tresoldi, Mio, Bordignon, Claudio, and Bregni, M.

Published
2001

36. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

Author

Cortelezzi, A, Gritti, G, Laurenti, L, Cuneo, Antonio, Ciolli, S, Di Renzo, N, Musto, P, Mauro, Fr, Cascavilla, N, Falchi, L, Zallio, F, Callea, V, Maura, F, Martinelli, S, Piciocchi, A, Reda, G, Foà, R, and on behalf of the GIMEMA Chronic Lymphoproliferative Disorders Working Party

Subjects
Chronic lymphocytic leukaemia, Alemtuzumab, Infection, Monoclonal antibodies
Published
2012

38. II.2. Gli asset socio culturali nei processi di internazionalizzazione dei territori. III.3. Procedure di valutazione: linee guida.IV.2. I criteri generali per la validazione dei programmi di partenariato internazionali.IV.4. La valutazione delle disponibilità di asset e del 'Δ asset'.La dimensione socio-culturale.V.2. Il caso Sicilia-Tunisia

Author

Bellini, N., Bramanti, Alberto, Ongaro, E., Barbieri, D., Crugnola, P., Lamanda, G., Martinez, I., Sumiraschi, Chiara, and Zallio, F.

Subjects
Internazionalizzazione, programmi, valutazione, socio-culturale, Regioni
Published
2008

40. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas

Author

Guglielmi, C., Martelli, M., Federico, M., Zinzani, Pl, Vitolo, U., Bellesi, G., Santini, G., Tarella, Corrado, Zallio, F., Pregno, P., DI RENZO, N., and Resegotti, L.

Subjects
Adult, Aged, 80 and over, Male, Salvage Therapy, relapse, Antibiotics, Antineoplastic, lymphoma, Middle Aged, Risk Assessment, Survival Analysis, Cohort Studies, Italy, Recurrence, lymphoma, relapse, prognosis, adults, transplantation, Antineoplastic Combined Chemotherapy Protocols, adults, Humans, Female, Lymphoma, Large B-Cell, Diffuse, Prospective Studies, prognosis, Aged, transplantation
Abstract

Our aim was to identify risk factors in adults with diffuse large cell lymphoma at first relapse.We studied 474 patients observed at 45 centers in Italy. Median time from diagnosis to relapse was 395 days, median age at relapse was 55 years and median follow-up from relapse was 3.3 years. Salvage therapy consisted of polychemotherapy in 79% of patients, monochemotherapy and/or radiotherapy and/or surgery alone in 16%, and palliative therapy in 5%. Salvage treatment was intensified with high-dose chemotherapy + stem cell transplant in 20% of patients. OS and PFS were compared by sex, International Prognostic Index at diagnosis, histology, B/T phenotype, initial treatment, salvage therapy, and features at relapse: time from diagnosis, LDH, stage, performance status and bone marrow involvement. Cox models, adjusted for salvage therapy, were performed with factors related to overall survival (OS) and progression-free survival (PFS).Overall response (complete + partial) was 63%, OS at 3 years 35% and PFS at 3 years 26%. Relapse within 12 months from diagnosis, elevated serum lactic dehydrogenase (LDH), advanced stage and poor performance status were independent adverse factors for OS and PFS. The cumulative number of adverse factors is proposed as prognostic index for DLCL at first relapse since it identifies risk groups (p0.0001) and has been validated (p=0.01). Moreover, it predicts OS and PFS in the selected group of patients with a responsive relapse (p0.0001).Delay from initial diagnosis, LDH, stage and performance status at relapse should be balanced in comparative studies of salvage therapy of adults with DLCL. Patients with more than 2 adverse factors are one third of all cases and deserve more effective salvage treatments.

Published
2001

44. Reduced-intensity conditioning followed by allogeneic transplantation can produce clinical and molecular remissions in relapsed non-Hodgkin's lymphoma

Author

Corradini, P., Bregni, M., Tarella, C., Olivieri, A., Dodero, A., Farina, L., Zallio, F., Leoni, P., Ciceri, F., Devizzi, L., Benedetti, F., Pogliani, E., Rambaldi, A., Locasciulli, A., Falda, M., Armando Santoro, Scime, R., Gianni, Am, Corradini, P, Bregni, M, Tarella, C, Olivieri, A, Dodero, A, Farina, L, Zallio, F, Leoni, P, Ciceri, Fabio, Devizzi, L, Benedetti, F, Pogliani, E, Rambaldi, A, Locasciulli, A, Falda, M, Santoro, A, Scime, R, and Gianni, Am

45. The start-up of the first HSCT center in the Iraqi Kurdistan: A cooperative project by the Hiwa cancer hospital, Sulaymaniyah, and the Italian agency for development cooperation

Author

Quattrocchi, S., Zallio, F., Yousif, A., Vittori, M., Verna, M., Vasta, S., Valdatta, C., Shrif, R., Sadiq, H., Real, G., Qadir, A., Possenti, M., Palmas, A., Ostuni, A., Noori, D., Mohammed, D., Mastria, A., Massei, M. S., Manna, Mahmood, T., Leone, R., Khoshnaw, N., Karim, D., Kareem, H., Ipsevich, F., Corrado GIRMENIA, Gabriel, M., Frigato, A., Dore, G., Sapio, E., Del Fante, C., Ciabatti, G., Canesi, M., Calabretta, C., Broggi, C., Ali, K., Ali, D., Ahmed, Z., Abdullah, C., Abdalrahman, N., Vacca, M., Rasool, L., Hassan, D., Rovelli, A., Othman, D., and Majolino, I.

46. OUTCOME OF ALLOGENEIC-HSCT IN 441 ADULT PATIENTS WITH PH-POSITIVE-ALL IN THE ERA OF TKI: A RETROSPECTIVE ANALYSIS OF THE ITALIAN BLOOD AND MARROW TRANSPLANTATION SOCIETY (GITMO)

Author

Candoni, A., Rambaldi, A., Fanin, R., Velardi, A., Arcese, W., Ciceri, F., Lazzarotto, D., Lussana, F., Olivieri, J., Grillo, G., Parma, M., Bruno, B., Sora, F., Bernasconi, P., Saccardi, R., Foa, R., Sessa, M., Bresciani, P., Giglio, F., Picardi, A., Busca, A., Sica, S., Diral, E., Colombo, A. A., Tringali, S., Santarone, S., Irrera, G., Mancini, S., Zallio, F., Malagola, M., Albano, F., Carella, A. M., Olivieri, A., Tecchio, C., alida dominietto, Vacca, A., Sorasio, R., Orciuolo, E., Risitano, A. M., Cortelezzi, A., Mammoliti, S., Oldani, E., and Bonifazi, F.

48. Efficiency of the distal screw in the distal movement of maxillary molars

Author

Cozzani, M., Zallio, F., Luca Lombardo, and Gracco, A.

Subjects
Dental Implants, Male, Palate, Hard, Titanium, Time Factors, Adolescent, Tooth Movement Techniques, Cephalometry, Bone Screws, Molar, Dental Materials, Treatment Outcome, Maxilla, Orthodontic Anchorage Procedures, Orthodontic Wires, Humans, Orthodontic Appliance Design, Bicuspid, Female, Stress, Mechanical, Child
Abstract

Conventionally, noncompliance distal movement of molars relies exclusively on intraoral anchorage. The distal screw, a distal jet appliance supplemented by two paramedian mini-implants, is an innovative alternative. The aim of this study was to evaluate the suitability of this device to move molars bodily and distally.The effects of the distal screw were evaluated in a sample of 18 consecutively treated preadolescent and adolescent individuals (nine females and nine males; mean age at the start of treatment, 11.2 years). Two conical mini-implants (length 11.0 mm, diameter 1.5 to 2.2 mm) were placed in the anterior paramedian area of the palate of each patient. The coil springs of the device were activated to deliver a force of 240 cN per side. The dental and skeletal effects were investigated on pre- and posttreatment cephalometric radiographs.The distal screw produced a Class I occlusion of the first molars by moving them distally 4.7 mm, which is more than conventional appliances can accomplish. Although this took longer than conventional devices (9.1 months), it had the advantage of a roughly 2.1-mm premolar distal movement (ie, no anchorage loss as with traditional techniques).The distal screw anchored by two palatal mini-implants allows not only translatory molar distal movement, but also distal movement of the maxillary first premolars, thereby avoiding characteristic anchorage loss.

49. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

Author

Alessandro Rambaldi, Carola Boccomini, Atto Billio, Francesco Angrilli, Roberto Passera, Marco Ladetto, Francesco Zallio, Gianpietro Semenzato, Liliana Devizzi, Fabio Ciceri, Barbara Mantoan, Fausto Rossini, Alessandra Dondi, Alessandra Tucci, Fabio Benedetti, Caterina Stelitano, Delia Rota-Scalabrini, Valerio Zoli, Paolo Corradini, Riccardo Bruna, Corrado Tarella, Maurizio Musso, Franco Narni, Caterina Patti, Guido Gini, Claudia Castellino, Tommasina Perrone, Anna Maria Barbui, Francesco Lanza, Anna Marina Liberati, Guido Parvis, Francesco Di Raimondo, Alessandro Massimo Gianni, Alessandro Pulsoni, Angela Gueli, Bruna R., Benedetti F., Boccomini C., Patti C., Barbui A. M., Pulsoni A., Musso M., Liberati A. M., Gini G., Castellino C., Rossini F., Ciceri F., Rota-Scalabrini D., Stelitano C., Di Raimondo F., Tucci A., Devizzi L., Zoli V., Zallio F., Narni F., Dondi A., Parvis G., Semenzato G., Lanza F., Perrone T., Angrilli F., Billio A., Gueli A., Mantoan B., Rambaldi A., Massimo Gianni A., Corradini P., Passera R., Ladetto M., Tarella C., Bruna, R., Benedetti, F., Boccomini, C., Patti, C., Barbui, A. M., Pulsoni, A., Musso, M., Liberati, A. M., Gini, G., Castellino, C., Rossini, F., Ciceri, F., Rota-Scalabrini, D., Stelitano, C., Di Raimondo, F., Tucci, A., Devizzi, L., Zoli, V., Zallio, F., Narni, F., Dondi, A., Parvis, G., Semenzato, G., Lanza, F., Perrone, T., Angrilli, F., Billio, A., Gueli, A., Mantoan, B., Rambaldi, A., Massimo Gianni, A., Corradini, P., Passera, R., Ladetto, M., and Tarella, C.

Subjects
Male, Oncology, Lymphoma, medicine.medical_treatment, advanced-stage follicular lymphoma, Follicular lymphoma, Kaplan-Meier Estimate, law.invention, 0302 clinical medicine, Cancer immunotherapy, Randomized controlled trial, Recurrence, immune system diseases, law, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Prospective cohort study, Lymphoma, Follicular, non-Hodgkin lymphoma, Remission Induction, Hematology, Middle Aged, Prognosis, Combined Modality Therapy, Treatment Outcome, Italy, chemoimmunotherapy, Female, Rituximab, Adult, Follow-Up Studies, Humans, Neoplasm Staging, Proportional Hazards Models, Young Adult, medicine.drug, medicine.medical_specialty, Sudden death, Article, NO, 03 medical and health sciences, Lymphoma, therapy, clinical trial, Internal medicine, medicine, Cancer staging, Chemotherapy, business.industry, Follicular, medicine.disease, business, 030215 immunology
Abstract

A prospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (R-HDS) versus conventional chemotherapy with rituximab (CHOP-R) as first-line therapy in 134 high-risk follicular lymphoma patients aged

Published
2019

50. Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti

Author

Lucia Farina, Anna Maria Gallina, Paolo Bernasconi, Marco Andreani, Elena Oldani, Mariarosaria Sessa, P Chiusolo, Valeria Miotti, Benedetto Bruno, Francesca Bonifazi, F. Lorentino, Pietro Pioltelli, Mario Luppi, Domenico Russo, Carlo Borghero, Angelo Michele Carella, Attilio Olivieri, Francesco Zallio, William Arcese, Ivana Celeghini, Teresa Lamparelli, G. Papalinetti, Fabio Benedetti, Giuseppe Milone, Stefano Guidi, Alessandro Rambaldi, Sonia Mammoliti, Ursula La Rocca, Franca Fagioli, Simona Pollichieni, Alessandra Picardi, Fabio Ciceri, Luca Vago, Massimo Martino, Ilaria Mangione, Francesca Patriarca, Paola Carluccio, Michela Cerno, Nicoletta Sacchi, Silvia Miccichè, Giorgia Saporiti, Picardi, A., Sacchi, N., Miotti, V., Lorentino, F., Oldani, E., Rambaldi, A., Sessa, M., Bruno, B., Cerno, M., Vago, L., Bernasconi, P., Arcese, W., Benedetti, F., Pioltelli, P., Russo, D., Farina, L., Fagioli, F., Guidi, S., Saporiti, G., Zallio, F., Chiusolo, P., Borghero, C., Papalinetti, G., La Rocca, U., Milone, G., Lamparelli, T., Carella, A. M., Luppi, M., Olivieri, A., Martino, M., Carluccio, P., Celeghini, I., Andreani, M., Gallina, A. M., Patriarca, F., Pollichieni, S., Mammoliti, S., Micciche, S., Mangione, I., Ciceri, F., and Bonifazi, F.

Subjects
Adult, medicine.medical_specialty, medicine.medical_treatment, Lymphocyte, Hematopoietic stem cell transplantation, Human leukocyte antigen, Gastroenterology, Bone Marrow, HLA matching, Italian origin, Unrelated hematopoietic stem cell transplantation, Internal medicine, medicine, Immunology and Allergy, Humans, Cumulative incidence, Registries, Alleles, Transplantation, business.industry, Hematopoietic Stem Cell Transplantation, Retrospective cohort study, Cell Biology, Hematology, Middle Aged, Settore MED/15, Prognosis, Hematologic Diseases, Neoplasm Recurrence, medicine.anatomical_structure, Local, Italy, Molecular Medicine, Methotrexate, Bone marrow, Stem cell, Neoplasm Recurrence, Local, business, medicine.drug
Abstract

HLA molecules are important for immunoreactivity in allogeneic hematopoietic stem cell transplantation (HSCT). The Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti promoted a retrospective observational study to evaluate HLA matching and the impact of allelic HLA mismatching and non-HLA factors on unrelated Italian HSCT outcomes. From 2012 to 2015, 1788 patients were enrolled in the study. The average donor age was 29 years and the average recipient age was 49 years. As a conditioning regimen, 71% of the patients received myeloablative conditioning. For GVHD prophylaxis, 76% received either antithymocyte or anti-T lymphocyte globulin, cyclosporine A, and methotrexate. Peripheral blood was the stem cell source in 80%. The median duration of follow-up was 53 months. Regarding HLA matching, 50% of donor-recipient pairs were 10/10 matched, 38% had 1 mismatch, and 12% had 2 or more mismatches. A total of 302 pairs shared Italian origin. Four-year overall survival (OS), progression-free survival, GVHD-free relapse-free survival, and relapse rates were 49%, 40%, 22%, and 34%, respectively. The 4-year NRM was 27%, and the 100-day cumulative incidence of grade ≥II acute GVHD (aGVHD) was 26%. In multivariate analysis, 9/10 and ≤8/10 HLA allele-matched pairs were associated with worse OS (P = .04 and. 007, respectively), NRM (P = .007 and P < .0001, respectively), and grade III-IV aGVHD (P = .0001 and. 01, respectively). Moreover, the incidences of grade II-IV aGVHD (P = .001) and chronic GVHD (P = .002) were significantly lower in Italian pairs. In conclusion, 10/10 HLA matching is a favorable prognostic factor for unrelated HSCT outcome in the Italian population. Moreover, the presence of 2 HLA-mismatched loci was associated with a higher NRM (P < .0001) and grade II-IV aGVHD (P = .006) and a poorer OS (P = .001) compared with 1 HLA-mismatched locus in early or intermediate disease phases. Finally, we found that Italian donor and recipient origin is a favorable prognostic factor for GVHD occurrence.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results